StockNews.com Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT)

Analysts at StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a report released on Tuesday. The firm set a “hold” rating on the stock.

ONCT has been the subject of a number of other reports. HC Wainwright lowered their target price on Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Northland Securities reiterated a “market perform” rating and set a $2.00 price objective on shares of Oncternal Therapeutics in a research report on Thursday, September 12th. Brookline Capital Management restated a “hold” rating on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Finally, Northland Capmk downgraded shares of Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 12th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $20.00.

Oncternal Therapeutics Trading Down 6.1 %

Shares of Oncternal Therapeutics stock opened at $1.07 on Tuesday. The firm has a market cap of $3.17 million, a PE ratio of -0.09 and a beta of 1.33. The stock has a 50 day moving average of $1.51 and a 200 day moving average of $5.06. Oncternal Therapeutics has a 12 month low of $1.03 and a 12 month high of $13.14.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Pasadena Private Wealth LLC purchased a new position in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned 0.84% of Oncternal Therapeutics at the end of the most recent quarter. 16.05% of the stock is owned by hedge funds and other institutional investors.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.